Literature DB >> 24572833

Acylated and unacylated ghrelin administration to blunt muscle wasting.

Simone Reano1, Andrea Graziani, Nicoletta Filigheddu.   

Abstract

PURPOSE OF REVIEW: Muscle wasting is a comorbidity often associated with a wide range of disorders that severely affects patient prognosis and quality of life. Ghrelin, through its receptor GHSR-1a, stimulates appetite and growth hormone (GH) release. Several studies indicate that ghrelin administration is a valid treatment for cachexia because it improves muscle mass and function, likely by restoring a positive energy balance. RECENT
FINDINGS: In addition to its GHSR-1a-mediated effects on muscle mass, ghrelin acts directly on skeletal muscle, wherein it exerts a protective activity against muscle wasting. This direct activity is independent of GHSR-1a and is shared by the unacylated form of ghrelin, which does not bind GHSR-1a and is devoid of the effects on appetite and GH release.
SUMMARY: Both the acylated and unacylated forms of ghrelin might have therapeutic potential for the treatment of skeletal muscle wasting.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24572833     DOI: 10.1097/MCO.0000000000000049

Source DB:  PubMed          Journal:  Curr Opin Clin Nutr Metab Care        ISSN: 1363-1950            Impact factor:   4.294


  13 in total

Review 1.  Cancer cachexia: understanding the molecular basis.

Authors:  Josep M Argilés; Sílvia Busquets; Britta Stemmler; Francisco J López-Soriano
Journal:  Nat Rev Cancer       Date:  2014-10-09       Impact factor: 60.716

Review 2.  Cancer-Mediated Muscle Cachexia: Etiology and Clinical Management.

Authors:  Thomas Siff; Parash Parajuli; Mohammed S Razzaque; Azeddine Atfi
Journal:  Trends Endocrinol Metab       Date:  2021-04-19       Impact factor: 10.586

Review 3.  Antifibrotic activity of acylated and unacylated ghrelin.

Authors:  Elia Angelino; Simone Reano; Michele Ferrara; Emanuela Agosti; Andrea Graziani; Nicoletta Filigheddu
Journal:  Int J Endocrinol       Date:  2015-04-16       Impact factor: 3.257

4.  Acylated and unacylated ghrelin inhibit atrophy in myotubes co-cultured with colon carcinoma cells.

Authors:  Xianliang Zeng; Sizeng Chen; Yang Yang; Zhao Ke
Journal:  Oncotarget       Date:  2017-08-24

Review 5.  Cancer-induced muscle wasting: latest findings in prevention and treatment.

Authors:  Zaira Aversa; Paola Costelli; Maurizio Muscaritoli
Journal:  Ther Adv Med Oncol       Date:  2017-03-08       Impact factor: 8.168

6.  AG and UAG induce β-casein expression via activation of ERK1/2 and AKT pathways.

Authors:  Sunan Li; Juxiong Liu; Qingkang Lv; Chuan Zhang; Shiyao Xu; Dongxue Yang; Bingxu Huang; Yalong Zeng; Yingjie Gao; Wei Wang
Journal:  J Mol Endocrinol       Date:  2016-02-12       Impact factor: 5.098

7.  Ghrelin rescues skeletal muscle catabolic profile in the R6/2 mouse model of Huntington's disease.

Authors:  Marie Sjögren; Ana I Duarte; Andrew C McCourt; Liliya Shcherbina; Nils Wierup; Maria Björkqvist
Journal:  Sci Rep       Date:  2017-10-24       Impact factor: 4.379

8.  Both ghrelin deletion and unacylated ghrelin overexpression preserve muscles in aging mice.

Authors:  Emanuela Agosti; Marilisa De Feudis; Elia Angelino; Roberta Belli; Maraiza Alves Teixeira; Ivan Zaggia; Edoardo Tamiso; Tommaso Raiteri; Andrea Scircoli; Flavio L Ronzoni; Maurizio Muscaritoli; Andrea Graziani; Flavia Prodam; Maurilio Sampaolesi; Paola Costelli; Elisabetta Ferraro; Simone Reano; Nicoletta Filigheddu
Journal:  Aging (Albany NY)       Date:  2020-07-26       Impact factor: 5.682

Review 9.  Pancreatic Cancer and Cachexia-Metabolic Mechanisms and Novel Insights.

Authors:  Kalliopi Anna Poulia; Panagiotis Sarantis; Dimitra Antoniadou; Evangelos Koustas; Adriana Papadimitropoulou; Athanasios G Papavassiliou; Michalis V Karamouzis
Journal:  Nutrients       Date:  2020-05-26       Impact factor: 5.717

Review 10.  Canine and feline obesity: a review of pathophysiology, epidemiology, and clinical management.

Authors:  John P Loftus; Joseph J Wakshlag
Journal:  Vet Med (Auckl)       Date:  2014-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.